Equities

Assure Tech Hangzhou Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Assure Tech Hangzhou Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)39.27
  • Today's Change-0.09 / -0.23%
  • Shares traded315.12k
  • 1 Year change+2.53%
  • Beta1.4039
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Assure Tech (Hangzhou) Co Ltd is a China-based company mainly engaged in the research and development of point-of-care testing (POCT) reagents and instruments. The Company's products include antigen and antibody raw materials, immunochromatographic reagents and testing equipment, and dry biochemical reagents and testing equipment. The Company's POCT products cover eight areas of drug testing, infectious disease testing, chronic disease testing, pregnancy testing, tumor testing, myocardial testing, biochemical testing, and allergen testing. The Company's products are sold to the United States, Germany, Britain, Canada and other countries.

  • Revenue in CNY (TTM)462.72m
  • Net income in CNY120.87m
  • Incorporated2008
  • Employees741.00
  • Location
    Assure Tech Hangzhou Co Ltd5FBuilding 4, No. 1418-50 Moganshan RoadHANGZHOU 310011ChinaCHN
  • Phone+86 57 185391552
  • Fax+86 57 188865920
  • Websitehttps://www.diareagent.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Getein Biotech Inc1.04bn181.90m4.41bn1.95k24.231.64--4.230.35870.35872.065.310.26831.682.68535,523.104.4110.906.3115.5367.5464.9616.4325.582.14--0.183931.15-14.933.77-20.06-8.024.62-2.48
Nanjing Medlander Medical Tech Co Ltd437.82m101.51m4.51bn582.0043.463.30--10.301.041.044.4713.680.28652.1815.40752,267.606.8111.967.5413.8969.1671.9823.7631.418.22--0.026848.4224.5710.6813.10-0.860123.21--
CareRay Digital Medical Technology CoLtd328.62m5.41m4.59bn282.00798.865.34--13.950.06510.06513.799.740.33921.693.661,165,314.000.53624.810.59725.2736.1340.001.5812.873.571.770.049734.948.904.9114.54-18.1985.59--
Thalys Medical Technology Group Corp1.25bn-240.46m4.59bn1.25k--4.20--3.68-1.35-1.356.555.190.47773.801.121,001,425.00-9.15-2.70-16.94-4.9318.2620.43-19.16-4.591.16-2.080.357---9.74-0.2204-31.95---24.80--
Chimin Health Management Co Ltd637.78m-165.28m4.59bn1.99k--3.27--7.20-0.3276-0.32761.242.670.25913.153.72319,848.50-6.700.4271-9.090.633527.9442.63-25.861.160.8238-8.240.330865.53-13.280.11518.81---1.88--
Innovita Biological Technology Co Ltd430.96m133.44m4.79bn547.0035.742.36--11.110.97780.97783.1514.840.19922.2812.73787,869.506.1718.666.5220.9776.4378.3430.9643.4216.16--0.002512.0529.9935.1141.9263.2528.63--
Hangzhou Ags Medtech Co Ltd668.70m272.95m4.92bn744.0018.011.98--7.363.373.378.2530.670.26733.3111.94898,793.6010.91--11.39--69.67--40.82--18.27--0.001--25.14--35.06------
Zhejiang Orient Gene Biotech Co Ltd842.11m-479.50m4.97bn2.28k--0.7816--5.90-2.48-2.484.3731.550.1071.443.39369,997.60-6.6821.19-7.7726.7434.8858.52-62.4332.423.86--0.046224.780.94617.65-33.06--138.80--
Assure Tech (Hangzhou) Co Ltd462.72m120.87m4.99bn741.0041.290.9667--10.790.95110.95113.6440.620.08092.222.17624,449.302.1123.692.3028.0130.3264.6126.1147.6511.28--0.001218.787.4220.8535.8528.6963.16--
Nanjing Vishee Medical Technology Co Ltd433.83m125.95m5.49bn639.0043.583.31--12.651.321.324.5317.310.24114.0014.42678,922.307.008.397.639.2061.2471.6229.0332.766.54--0.018259.13-13.454.64-25.160.447439.73--
SWS Hemodialysis Care Co Ltd733.59m113.43m5.52bn1.10k48.793.13--7.520.35380.35382.295.520.35772.806.23665,688.205.235.685.836.5445.7145.7914.6116.065.25--0.001428.46-17.8031.86-63.55--24.70--
Data as of Feb 13 2026. Currency figures normalised to Assure Tech Hangzhou Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

15.86%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 30 Jun 20253.01m9.60%
China Merchants Fund Management Co., Ltd.as of 30 Jun 2025680.90k2.17%
Bosera Asset Management Co., Ltd.as of 30 Jun 2025613.97k1.96%
Xinyuan Asset Management Co., Ltd.as of 30 Jun 2025203.65k0.65%
Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2025101.00k0.32%
Guotai Asset Management Co., Ltd.as of 30 Jun 202582.39k0.26%
E Fund Management Co., Ltd.as of 30 Jun 202582.04k0.26%
Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 202575.00k0.24%
Taikang Asset Management Co. Ltd.as of 30 Jun 202570.00k0.22%
China Asset Management Co., Ltd.as of 30 Jun 202556.25k0.18%
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.